iberdomide,bms-986393,dexamethasone,mezigdomide,alnuctamab,idecabtagene vicleucel
merck,2seventy bio,bms,emergent biosolutions
['220,mm,001', 'iberdomide', 'cc,220,mm,001', 'cc-93269', 'abecma', 'mezigdomide', 'multiple myeloma', 'alnuctamab', 'cc,93269,mm,001', 'mm-001', 'cc-220', 'bms-986393', 'bristol', 'emergent ', 'bms', '$bmy']
bristol myers squibb $bmy announces first disclosures and new data at #ash22, demonstrating commitment to raising standards in treatment through broad multiple myeloma portfolio #gprc5d car-t / abecma / #bcma tce alnuctamab / #cellmods 
Biotellytics / https://t.co/37itIfRolp = business intel service on listed European Bios / Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design)